Due to the growing anti-China sentiment in India, manufacturers in the metformin hydrochloride API market are boosting their production capabilities to decrease reliance on China. Disruptions to supplies from China due to the COVID-19 pandemic have been a major factor for manufacturers to bolster local production of active pharmaceutical ingredients (APIs).
Though India is known as the pharmacy of the world for its massive production capabilities in generic drugs and vaccines, China is emerging as a stiff competition to India by accounting for half of the world API supply. Indian drug companies are turning to local producers in the metformin hydrochloride API market to end their reliance on China, as ties between the two countries sourced after a deadly border clash in June 2020. Executives at India’s Cipla, Biocon, Cadila Healthcare, and Sun Pharmaceutical are keen on reducing the dependence on richer rivals of raw materials.
To know the scope of our report Get a Sample on Metformin Hydrochloride API Market
Metformin hydrochloride (metformin HCl) is widely used as the first choice of medication for type 2 diabetes. However, processing of this API can be challenging and most dosage forms available on the market are prepared by wet granulation. In order to overcome the challenges of poor powder flow, lump formation glidants are being used and the ratio between pre- and main compression is being optimized to obtain tablets possessing suitable quality attributes. Manufacturers in the metformin hydrochloride API market are ensuring the unit operations of blending the API with the glidant candidates and tableting on a rotary press are being carried out by continuous processing.
Continuous manufacturing is drawing the attention of stakeholders in the pharmaceutical industry, owing to its advantages of reduction in scale-up challenges and real-time quality control.
Get a glimpse of the in-depth analysis through our Report Brochure
Lupin Pharmaceuticals Inc. - an innovation-led pharmaceutical company in the U.S. has announced the launch of its Metformin HCl ER Tablets, 500 mg, and 1000 mg to the market, which are a generic equivalent of Santarus Inc.’s Glumetza® HCl ER Tablets, 500 mg, and 1000 mg. Manufacturers in the metformin hydrochloride API market are introducing tablets that are an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.
Since high prevalence of diabetes mellitus in patients is characterized by a persistently elevated blood glucose associated with absent or inadequate pancreatic insulin secretion, manufacturers in the metformin hydrochloride API market are increasing their production capacities for tablets.
The metformin hydrochloride API market is estimated to reach US$ 500 Mn by 2031. There is a growing demand for drugs that can control blood sugar levels for patients suffering from type 2 diabetes. Metformin HCl tablets help to reduce the amount of sugar produced by the liver, limit the amount of sugar absorbed into the body from the diet, and make insulin receptors more sensitive, which helps the body respond better to its own insulin.
Manufacturers in the metformin hydrochloride API market are increasing the availability of liquid and tablet forms of metformin HCl. Metformin HCl tablets are being publicized as oral anti-hyperglycemic medicines that are of paramount importance in the control and treatment of type 2 diabetes. The raw material powder of metformin hydrochloride API inhibits the process of the liver to convert glycogen into sugar. Manufacturers are increasing awareness about possible side effects such as digestive problem and nausea to improve patient quality of life.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Indian drug companies are eyeing reliable local vendors who can promise consistency and competitive prices, due to the growing anti-China sentiment and reduced reliance on richer rival of raw materials during the COVID-19 pandemic. The metformin hydrochloride API market is witnessing the launch of new tablets that are equivalent to Santarus Inc.’s Glumetza® HCl ER Tablets, 500 mg, and 1000 mg. However, the processing of this API is potentially challenging, and most dosage forms available on the market are prepared by wet granulation. Hence, manufacturers should adopt continuous manufacturing and use of glidant candidates to process powdered form of metformin hydrochloride APIs.
Metformin Hydrochloride API Market – Segmentation
| Product |
|
| End User |
|
| Dosage Form |
|
| Region |
|
Metformin hydrochloride API market is estimated to reach US$ 500 Mn by 2031
Metformin hydrochloride API market is projected to expand at a CAGR of ~5% from 2021 to 2031
Metformin hydrochloride API market is driven by rise in prevalence of diabetes, surge in awareness about diabetes
The metformin hydrochloride segment dominated the global metformin hydrochloride API market, and the trend is anticipated to continue during the forecast period.
Key players operating in the global metformin hydrochloride API market are Auro Laboratories Limited, Abhilasha Pharma Pvt. Ltd., Stanex Drugs & Chemicals Pvt. Ltd., Fengchen Group Co., Ltd., NS Chemicals
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Metformin Hydrochloride API Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Metformin Hydrochloride API Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Top 3 Players Operating in the Market Space
5.2. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.3. Top Companies by Production Capacity, Production Volume, and Production Amount
5.4. Top Countries by Production Capacity, Production Volume, and Production Amount
5.5. Top Countries by Consumption Volume and Consumption Amount
5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
6. Global Metformin Hydrochloride API Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Metformin Hydrochloride
6.3.2. Metformin Hydrochloride DC
6.3.3. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Metformin Hydrochloride API Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Pharmaceutical Companies
7.3.2. Contract Research Organizations
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Metformin Hydrochloride API Market Analysis and Forecast, by Dosage Form
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Dosage Form, 2017–2031
8.3.1. Tablet
8.3.2. Extended Release Tablet
8.3.3. Oral Solution
8.4. Market Attractiveness Analysis, by Dosage Form
9. Global Metformin Hydrochloride API Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Metformin Hydrochloride API Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Metformin Hydrochloride
10.2.2. Metformin Hydrochloride DC
10.2.3. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical Companies
10.3.2. Contract Research Organizations
10.3.3. Others
10.4. Market Value Forecast, by Dosage Form, 2017–2031
10.4.1. Tablet
10.4.2. Extended Release Tablet
10.4.3. Oral Solution
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By End-user
10.6.3. By Dosage Form
10.6.4. By Country
11. Europe Metformin Hydrochloride API Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Metformin Hydrochloride
11.2.2. Metformin Hydrochloride DC
11.2.3. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Pharmaceutical Companies
11.3.2. Contract Research Organizations
11.3.3. Others
11.4. Market Value Forecast, by Dosage Form, 2017–2031
11.4.1. Tablet
11.4.2. Extended Release Tablet
11.4.3. Oral Solution
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By End-user
11.6.3. By Dosage Form
11.6.4. By Country/Sub-region
12. Asia Pacific Metformin Hydrochloride API Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Metformin Hydrochloride
12.2.2. Metformin Hydrochloride DC
12.2.3. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Pharmaceutical Companies
12.3.2. Contract Research Organizations
12.3.3. Others
12.4. Market Value Forecast, by Dosage Form, 2017–2031
12.4.1. Tablet
12.4.2. Extended Release Tablet
12.4.3. Oral Solution
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By End-user
12.6.3. By Dosage Form
12.6.4. By Country/Sub-region
13. Latin America Metformin Hydrochloride API Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Metformin Hydrochloride
13.2.2. Metformin Hydrochloride DC
13.2.3. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Pharmaceutical Companies
13.3.2. Contract Research Organizations
13.3.3. Others
13.4. Market Value Forecast, by Dosage Form, 2017–2031
13.4.1. Tablet
13.4.2. Extended Release Tablet
13.4.3. Oral Solution
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By End-user
13.6.3. By Dosage Form
13.6.4. By Country/Sub-region
14. Middle East & Africa Metformin Hydrochloride API Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Metformin Hydrochloride
14.2.2. Metformin Hydrochloride DC
14.2.3. Others
14.3. Market Value Forecast, by End-user, 2017–2031
14.3.1. Pharmaceutical Companies
14.3.2. Contract Research Organizations
14.3.3. Others
14.4. Market Value Forecast, by Dosage Form, 2017–2031
14.4.1. Tablet
14.4.2. Extended Release Tablet
14.4.3. Oral Solution
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By End-user
14.6.3. By Dosage Form
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Auro Laboratories Limited
15.3.1.1. Company Overview
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Abhilasha Pharma Pvt. Ltd.
15.3.2.1. Company Overview
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Stanex Drugs & Chemicals Pvt. Ltd.
15.3.3.1. Company Overview
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Fengchen Group Co., Ltd.
15.3.4.1. Company Overview
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. NS Chemicals
15.3.5.1. Company Overview
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Midas Pharma GmbH
15.3.6.1. Company Overview
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Harman Finochem Ltd.
15.3.7.1. Company Overview
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Aarti Drugs Ltd.
15.3.8.1. Company Overview
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Bayer AG
15.3.9.1. Company Overview
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
15.3.10. Ipca Laboratories Ltd.
15.3.10.1. Company Overview
15.3.10.2. Company Financials
15.3.10.3. Growth Strategies
15.3.10.4. SWOT Analysis
15.3.11. Panacea Biotech Ltd.
15.3.11.1. Company Overview
15.3.11.2. Company Financials
15.3.11.3. Growth Strategies
15.3.11.4. SWOT Analysis
15.3.12. Aristopharma Ltd.
15.3.12.1. Company Overview
15.3.12.2. Company Financials
15.3.12.3. Growth Strategies
15.3.12.4. SWOT Analysis
15.3.13. Sihuan Pharmaceutical Holdings Group Ltd.
15.3.13.1. Company Overview
15.3.13.2. Company Financials
15.3.13.3. Growth Strategies
15.3.13.4. SWOT Analysis
15.3.14. Intas Pharmaceuticals Ltd.
15.3.14.1. Company Overview
15.3.14.2. Company Financials
15.3.14.3. Growth Strategies
15.3.14.4. SWOT Analysis
15.3.15. Bal Pharma Limited
15.3.15.1. Company Overview
15.3.15.2. Company Financials
15.3.15.3. Growth Strategies
15.3.15.4. SWOT Analysis
15.3.16. Sohan Healthcare Pvt. Ltd.
15.3.16.1. Company Overview
15.3.16.2. Company Financials
15.3.16.3. Growth Strategies
15.3.16.4. SWOT Analysis
15.3.17. JD Chem (I)
15.3.17.1. Company Overview
15.3.17.2. Company Financials
15.3.17.3. Growth Strategies
15.3.17.4. SWOT Analysis
15.3.18. Kothari Phytochemicals & Industries Ltd.
15.3.18.1. Company Overview
15.3.18.2. Company Financials
15.3.18.3. Growth Strategies
15.3.18.4. SWOT Analysis
15.3.19. Turtle Pharma Private Limited
15.3.19.1. Company Overview
15.3.19.2. Company Financials
15.3.19.3. Growth Strategies
15.3.19.4. SWOT Analysis
15.3.20. Shijiazhuang Polee pharmaceutical Co., Ltd.
15.3.20.1. Company Overview
15.3.20.2. Company Financials
15.3.20.3. Growth Strategies
15.3.20.4. SWOT Analysis
15.3.21. Shouguang Fukang Pharmaceutical Co., Ltd.
15.3.21.1. Company Overview
15.3.21.2. Company Financials
15.3.21.3. Growth Strategies
15.3.21.4. SWOT Analysis
15.3.22. USV Private Limited
15.3.22.1. Company Overview
15.3.22.2. Company Financials
15.3.22.3. Growth Strategies
15.3.22.4. SWOT Analysis
15.3.23. Exemed Pharmaceuticals
15.3.23.1. Company Overview
15.3.23.2. Company Financials
15.3.23.3. Growth Strategies
15.3.23.4. SWOT Analysis
15.3.24. Farmhispania Group
15.3.24.1. Company Overview
15.3.24.2. Company Financials
15.3.24.3. Growth Strategies
15.3.24.4. SWOT Analysis
15.3.25. Shandong Keyuan Pharmaceutical Co., Ltd.
15.3.25.1. Company Overview
15.3.25.2. Company Financials
15.3.25.3. Growth Strategies
15.3.25.4. SWOT Analysis
15.3.26. Merck KGaA
15.3.26.1. Company Overview
15.3.26.2. Company Financials
15.3.26.3. Growth Strategies
15.3.26.4. SWOT Analysis
15.3.27. Taj API
15.3.27.1. Company Overview
15.3.27.2. Company Financials
15.3.27.3. Growth Strategies
15.3.27.4. SWOT Analysis
15.3.28. Vistin Pharma AS
15.3.28.1. Company Overview
15.3.28.2. Company Financials
15.3.28.3. Growth Strategies
15.3.28.4. SWOT Analysis
15.3.29. Wanbury Limited
15.3.29.1. Company Overview
15.3.29.2. Company Financials
15.3.29.3. Growth Strategies
15.3.29.4. SWOT Analysis
List of Tables
Table 01: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 03: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 04: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 06: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 07: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 08: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 09: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 11: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 13: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 17: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 19: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
Table 21: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 23: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031
List of Figures
Figure 01: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 03: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 04: Global Metformin Hydrochloride API Market Value (US$ Mn), by Metformin Hydrochloride, 2017–2031
Figure 05: Global Metformin Hydrochloride API Market Value (US$ Mn), by Metformin Hydrochloride DC, 2017–2031
Figure 06: Global Metformin Hydrochloride API Market Value (US$ Mn), by Others, 2017–2031
Figure 07: Global Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 08: Global Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Figure 09: Global Metformin Hydrochloride API Market Value (US$ Mn), by Pharmaceutical Companies, 2017–2031
Figure 10: Global Metformin Hydrochloride API Market Value (US$ Mn), by Contract Research Organizations, 2017–2031
Figure 11: Global Metformin Hydrochloride API Market Value (US$ Mn), by Others, 2017–2031
Figure 12: Global Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 13: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 14: Global Metformin Hydrochloride API Market Value (US$ Mn), by Tablet, 2017–2031
Figure 15: Global Metformin Hydrochloride API Market Value (US$ Mn), by Extended Release Tablet, 2017–2031
Figure 16: Global Metformin Hydrochloride API Market Value (US$ Mn), by Oral Solution, 2017–2031
Figure 17: Global Metformin Hydrochloride API Market Value Share Analysis, by Region, 2020 and 2031
Figure 18: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Region, 2021–2031
Figure 19: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 20: North America Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 21: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 22: North America Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 23: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 24: North America Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 25: North America Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Figure 26: North America Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 27: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 28: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: Europe Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 30: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 31: Europe Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 32: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 33: Europe Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 34: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Figure 35: Europe Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 36: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 37: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: Asia Pacific Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 39: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 40: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 41: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 42: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 43: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Figure 44: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 45: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 46: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 47: Latin America Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 48: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 49: Latin America Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 50: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 51: Latin America Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 52: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Figure 53: Latin America Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031
Figure 54: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031
Figure 55: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 56: Middle East & Africa Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 57: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 58: Middle East & Africa Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031
Figure 59: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031
Figure 60: Middle East & Africa Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031
Figure 61: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Metformin Hydrochloride API Market Insights, 2021 - 2031
